Rituximab for severe mucous membrane pemphigoid: Safe enough to be drug of first choice?

Archives of Dermatology

Volumn 147, Issue 7, 2011, Pages 855-856

  Hertl, Michael ^a   Bernard, Philippe ^b   Borradori, Luca ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DAPSONE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADJUVANT THERAPY; B LYMPHOCYTE; BACTERIAL INFECTION; BASEMENT MEMBRANE; COMPLEMENT DEPOSITION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG SAFETY; EDITORIAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; IMMUNOGLOBULIN DEPOSITION; IMMUNOTHERAPY; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PARANEOPLASTIC PEMPHIGUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VIRUS INFECTION;

EID: 79960576500     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.167     Document Type: Editorial

References (18)

1. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843-849.
2. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370-379. (Pubitemid 34226335)
3. Bruch-Gerharz D, Hertl M, Ruzicka T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007;17(3):191-200. (Pubitemid 46847780)
4. Bedane C, Prost C, Ingen-Housz-Oro S, Joly P, Bernard P. Mucous membrane pemphigoid: guidelines for the diagnosis and treatment. Ann Dermatol Venereol. 2011;138(3):259-263.
5. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol. 2002;138(3):380-384. (Pubitemid 34226336)
6. Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients [published online November 4, 2010]. J Eur Acad Dermatol Venereol. doi:10.1111/j.1468-3083.2010.03889.x.
7. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6(5):366-373.
8. Feist E, Dörner T. Rituximab [in German]. Z Rheumatol. 2010;69(7):594-600.
9. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hügli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137(3):269-272. (Pubitemid 32240777)
10. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552. (Pubitemid 47236279)
11. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128(12):2745-2747.
12. Hertl M, Eming R, Borradori L. Rituximab (anti-CD20 monoclonal antibody) - ultimate or first choice in pemphigus? Dermatology. 2007;214(4):275-277. (Pubitemid 46659007)
13. Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128(12):2859-2869.
14. Müller R, Hunzelmann N, Baur V, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris [published online June 30, 2010]. Dermatol Res Pract. doi:10.1155/2010/321950.
15. Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol. 2009;129(2):289-301.
16. Black AP, Seneviratne SL, Jones L, et al. Rapid effector function of circulating NC16A-specific T cells in individuals with mucous membrane pemphigoid. Br J Dermatol. 2004;151(6):1160-1164. (Pubitemid 40030162)
17. Niedermeier A, Eming R, Pfütze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143(2):192-198. (Pubitemid 46294584)
18. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352-356. (Pubitemid 46095965)